Ancillary Cost-Effectiveness Analysis (BMT CTN 1101)

Cancer Prevention Program

Ancillary Cost-Effectiveness Analysis

The Bone Marrow Transplant (BMT) Clinical Trials Network (CTN) is investigating the best graft source for adult patients requiring donor cells sources for transplantation. A cost effectiveness analysis alongside 1101 will use clinical information from the trial, together with insurance claims data to determine the cost-effectiveness of cord blood vs. haplo matched relatives. BMT is one of the most expensive interventions in health care and is financially burdensome for families. Studies suggest that financial distress adversely impacts quality of life and may impair survival. Beyond finding the most cost-effective graft source, the parallel economic study of CTN 1101 provides a unique opportunity to prospectively evaluate the financial impact of BMT on patients and families. The results of this analysis can be used to help patients and providers make decisions that can reduce their financial burden, and to encourage insurers to implement BMT coverage policies that maximize clinical and cost-effectiveness.

Dr. Scott Ramsey, MD, PhD
Member, HICOR, Cancer Prevention Program

More Information

Funding Agency:
National Institutes of Health
NIH Project Report 

Jordan Steelquist